Assessing The Effectiveness of Growth Hormone Releasing Protein-6 in Improving Human Oocyte Maturation and Meiotic Progression in <i>In Vitro</i> Maturation Culture Media.
This experimental study investigated the potential of Growth Hormone Releasing Protein-6 (GHRP-6), a ghrelin hormone agonist, to improve in vitro maturation (IVM) of human oocytes. Researchers collected 240 human germinal vesicle (GV) oocytes and cultured them in varying concentrations of GHRP-6, comparing outcomes against a blastocyst single-step culture medium (control) and human tubal fluid (HTF) 10% (sham). Maturation rates were tracked over two days. A subset of 164 GV oocytes was then used to assess gene expression of CENP-E (associated with meiotic progression) and LINGO2 (a membrane protein gene) via real-time PCR after 24 hours of culture. The study found that a specific concentration of GHRP-6 produced the highest maturation rates on both day one and day two, outperforming both comparison media. However, real-time PCR analysis revealed that GHRP-6 did not significantly elevate expression of either CENP-E or LINGO2 in metaphase II oocytes, suggesting nuclear maturation was promoted without a corresponding improvement in cytoplasmic maturation markers. Key limitations include the absence of downstream developmental outcomes (e.g., fertilization or embryo quality data), a relatively small oocyte sample, and the lack of blinded assessment or patient-level randomization.